By the mid-2000s, no segment of the $ 180 billion global medical device industry was dynamic, how to market drug eluting stents (DES). In the U.S., accounting for nearly three-quarters of the total market DES, only two companies had regulatory approval to sell small devices: Johnson & Johnson and Boston Scientific. Together the two organizations is expected DES 2005 sales of approximately $ 5.5 billion - 36% from 2004. Forecasts called for a segment of the more than $ 7 billion by 2008. Partly due to their size, market DES was one of the most competitive and challenging sectors in the medical device industry. Competitive environment was marked by intense rivalry and suffering from fierce litigation over intellectual property rights. However, it is also characterized by a complex partnership between the companies, collaboration and licensing agreements. While Des was shown to significantly reduce restenosis, new security issues were new, related to the development of life-threatening blood clots associated with dec.
Some controversy existed regarding the costs / benefits of dec. And the product recalls and software failures were common, as companies seek to bring new technologies to market DES. Against this background, the segment is characterized by dramatic fluctuations in the stock market. Despite all this, the future looks promising dec. "Hide
by Stefanos Zenios, Lyn Denend Source: Stanford Graduate School of Business 43 pages. Publication Date: February 13, 2006. Prod. #: OIT50-PDF-ENG
Related Case Solutions & Analyses:
Mike Mayo Takes on Citigroup (A)
Measuring Impairment at Dofasco
Now You See It Now You Do Not: The Case Of Jet Airways And Its Accounting Policies
Rethinking the War for Talent
Staples.com
RENAULT TRUCKS: REMANUFACTURING AS A STRATEGIC ACTIVITY
Biosensors International Group: Valuation and Impairment Testing of Intangibles
Info-Tech Research Group
Transportation Displays, Inc. (D): Exiting from a Successful Restructuring
“Buy”, “Sell”, or “Hold”: Analyzing the Analysts’ Recommendations
